Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin and Ortho-Cyclen Interaction Study
NCT02494609Phase 1Unknown
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Jul 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotagliflozin in type 1 diabetes mellitus (T1D), type 2 diabetes mellitus (T2DM) and heart failure (HF) (3 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoints: Plasma concentration of sotaglifozin at Day 64 and Plasma concentration of norgestimate/ethinyl estradiol at Day 64. Status: unknown.
02
Drugs
sotagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on NCT02494609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494609.